Review: Immunoglobulin light chain amyloidosis - The archetype of structural and pathogenic variability

Journal of Structural Biology

Volumn 130, Issue 2-3, 2000, Pages 280-289

  Bellotti, Vittorio ^a   Mangione, Palma ^a   Merlini, Giampaolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; AMYLOIDOSIS; CONFORMATIONAL TRANSITION; HUMAN; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROCESSING; PROTEIN TERTIARY STRUCTURE; REVIEW; TISSUE SPECIFICITY;

EID: 0033855656     PISSN: 10478477     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsbi.2000.4248     Document Type: Review

References (68)

1. Transthyretin mutant exert cytotoxicity during amyloid formation
2. Complementary DNA sequence of human amyloidogenic immunoglobulin light chains precursors
3. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity
4. Use of an anti-idiotypic monoclonal antibody in studying amyloidogenic light chains in cells, urine and fibrils: Pathophysiology and clinical implications
5. Structural and functional characterization of three human immunoglobulin κ light chains with different pathological implications
6. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients
7. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients
8. Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with distinctly different clinical outcomes
9. Amino acid sequence of a λ VI primary (AL) amyloid protein (WLT)
10. Binding of 2,4-dinitrophenyl compounds and other small molecules to a crystalline lambda-type Bence-Jones dimer
11. Removal of the N-terminal hexapeptide from human β2-microglobulin facilitates protein aggregation and fibril formation
12. The precursor molecule of a Vλ II immunoglobulin light chain derived amyloid fibril protein circulates precleaved
13. Structural characterisation of kII INC, a new amyloid immunoglobulin
14. A glycosilated Bence Jones protein and its autologous amyloid light chain containing potentially amyloidogenic residues
15. New drug therapy of amyloidoses: Resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin
16. Allogeneic bone marrow transplantation for systemic AL amyloidosis
17. Creation of 'amyloid' fibrils from Bence Jones proteins in vitro
18. Organ-specific (localized) synthesis of Ig light chain amyloid
19. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons
20. Imaging amyloidosis with radiolabelled SAP
21. A role for destabilizing amino acid replacements in light chain amyloidosis
22. Patterns of amyloidosis and their association with plasma cell dyscrasias, monoclonal immunoglobulins and Bence Jones proteins
23. Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen
24. Interaction between glycosaminoglycans and immunoglobulin light chains
25. Alternative conformations of amyloidogenic proteins govern their behavior
26. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease
27. Complete amino acid sequence determinations demonstrate identity of the urinary Bence Jones protein (BJP-DIA) and the amyloid fibril protein (AL-DIA) in a case of AL-amyloidosis
28. Reduction of disulfide bonds in an amyloidogenic Bence Jones protein leads to formation of amyloid like fibrils in vitro
29. Amyloid disease: Abnormal protein aggregation in neurodegeneration
30. Primary systemic amyloidosis: Resolution of the nephrotic syndrome with melphalan and prednisone
31. Diffusible non fibrillar ligands derived from Aβ 1-42 are potent central nervous system neurotoxins
32. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
33. The formation of amyloid-like fibrils in vitro from Bence Jones Proteins of the V lambda I subclass
34. Comparison of the amino acid sequences of ten kappa I amyloid proteins for amyloidogenic sequences
35. Proteoglycans and the extracellular matrix in amyloidosis
36. Molecular heterogeneity and γ-carboxy-glutamic acid content of Bence Jones proteins, possible relevance to amyloidogenicity
37. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis
38. Treatment Of AL amyloidosis with 4'-lodo-4'-deoxydoxorubicin: An update
39. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients
40. Pathogenic potential of human monoclonal immunoglobulin light chains: Relationship of in vitro aggregation to in vivo organ deposition
41. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: Improved in vivo folding and physical characterization of an engineered scFv fragment
42. Structural analysis of the amyloidogenic κ Bence Jones protein (FUR)
43. Anatomy of the antibody molecule
44. Amyloid P component. A critical review
45. AL amyloidosis: Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies
46. Evidence that amyloidogenic light chains undergo antigen-driven selection
47. Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis
48. Local water bridges and protein conformational stability
49. Tertiary structure of human λ 6 light chains
50. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains
51. The structure of an entire non covalent immunoglobulin kappa light-chain dimer (Bence-Jones protein) reveals a weak and unusual constant domains association
52. Glycoproteins: Their structure, biosynthesis and possible clinical implications
53. Tertiary structure of an amyloid immunoglobulin light chain protein: A proposed model for amyloid fibril formation
54. The crystal structure of amyloidogenic Leu55-Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils
55. The complete amino acid sequence of a prototype immunoglobulin-λ light chain type amyloid fibril protein AR
56. Structural studies of the variable region of immunoglobulin light chain-type amyloid fibril protein
57. Bence Jones proteins and light chain of immunoglobulins. Preferential association of the λ VI subgroup of human light chains with amyloidosis AL
58. Light chain associated amyloid deposits comprised of a novel κ constant domain
59. Induction in mice of human light-chain-associated amyloidosis
60. Molecular structure of the amyloid forming protein κ I BRE
61. A molecular model for self assembly of amyloid fibrils: Immunoglobulin light chains
62. Antigen recognition by an antibody light chain
63. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters
64. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis
65. Thermodynamic instability of human lambda 6 light chains: Correlation with fibrillogenicity
66. Glycosilation of a VH residue of a monoclonal antibody against α(1-6) dextran increases its affinity for antigen
67. Immunoglobulin deposition disorder
68. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4